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ABSTRACT 
Objective: To determine “Is L-carnitine an effective treatment to improve the quality of life for 
patients with Rett Syndrome?”   
 
Study Design: Review of all English language randomized controlled trials and cohort trials from 
1999-2007.   
 
Data Sources: Randomized, placebo-controlled, double-blind crossover trial, randomized 
controlled trial, and cohort trial comparing L-carnitine to placebo or control group were found 
using OVID MEDLINE, and Cochrane Databases 
 
Outcomes Measured: The trials measured the effects of L-carnitine on physical well-being, 
motor skills, sleep efficiency, physical activity, and cardiac dysautonomia using the following 
assessment tools: The Rett Syndrome: Symptom Severity Index (RT:SSI), Patient Well-Being 
Index, SF-36 Health Survey, Hand Apraxia Scale, RS Motor Behavioral Assessment, 7 day-night 
sleep diary, TriTrac-R3D ergometers, electrocardiogram.  
 
 
Results: Two studies demonstrated that the patient well being, behavior/social and 
orofacial/respiratory motor skills, sleep efficiency, sleep latency, proportion of total sleep that 
occurred during the day, energy level, communication skills, expressive language, and teeth 
grinding all improved with L-carnitine treatment.  The third study demonstrated a reduction in 
the risk for cardiac arrhythmias in treatment with L-carnitine.  Parents/caregivers of participants 
in the study reported minor side effects with treatment, but no major side effects were reported.   
 
Conclusion: Based on the three trials, L-carnitine does improve the quality of life in patients with 
Rett Syndrome. 
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Introduction 
Rett Syndrome is a severe neurodevelopmental disorder that primarily affects females 
and is defined by progressive loss of intellectual functioning and fine and gross motor skills, 
deceleration of head growth, and the development of stereotypic hand movements occurring after 
a period of normal development.
1,2,3
  The risk of sudden death is increased in Rett Syndrome 
patients due to the occurrence of lethal arrhythmias, which can be related to long QT intervals 
and/or low heart rate variability.
3
   
Rett Syndrome is considered to be the second most common cause, after Down 
syndrome, of severe mental retardation in girls.  Its worldwide prevalence rate ranges from 
1:10,000 to 1:23,000 live female births.
1
 Although the exact cost of medical care for patients 
with Rett Syndrome is unknown, the syndrome is extremely difficult to manage and for some 
health insurance policies it can be filed under a “pre-existing condition” which makes it nearly 
impossible to obtain coverage for these patients.  Also, the number of healthcare visits per year 
for patients with Rett Syndrome varies depending on the severity of the disease and other 
existing medical conditions.   
The etiology of Rett Syndrome is unknown; however, in 80% of cases there is a mutation 
of a methyl-CpG-binding protein 2 (MECP2).
3
   
No treatments for Rett Syndrome as a whole currently exist; however, there are a variety 
of ways to minimize the effects of Rett Syndrome by treating specific symptoms.  Current 
therapies include physical therapy, occupational therapy, speech-language therapists, anti-seizure 
medication, OTC medications for constipation and indigestion.  Another proposed therapy that is 
being researched is treatment with L-carnitine.  Evidence suggests that an underlying defect in 
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Rett Syndrome may lie within mitochondrial energy production, which can interfere with the 
active cellular carnitine uptake process.
1,2,3
   
Objective 
The objective of this systematic review is to determine whether or not “Is L-carnitine an 
effective treatment to improve the quality of life for patient with Rett Syndrome?”  Previous 
studies have shown that a plasma carnitine deficiency exists in some patients with Rett 
Syndrome; therefore it is suggested that Rett Syndrome patients will have positive outcomes 
when treated with L-carnitine.   
Methods 
Randomized Controlled Trials were searched for those with a female patient population 
over the age of 2 with clinically diagnosed Rett Syndrome, as well as those whose treatment 
interventions include L-carnitine.  In addition, only those articles that compared the treatment 
groups receiving L-carnitine to a placebo group or control group were considered.  Under these 
criteria, one randomized, placebo-controlled, double-blind crossover trial, one cohort, and one 
randomized controlled trial were identified and included in this review.   
A detailed search was completed by the author using the following search engines: OVID 
MEDLINE, Cochrane Database of Randomized Controlled Trials, and Cochrane Database of 
Systemic Reviews.  The key words “Rett Syndrome” and “L-Carnitine” were used in 
combination to search for English articles and all of the resulting articles were published in peer-
reviewed journals from 1999 to 2007.  The articles were selected based on the importance of the 
outcomes to the patient (Patient Oriented Evidence That Matters, POEMS).  Studies that were 
included were those that were randomized, controlled, and based on patient oriented outcome.  
Those that were excluded were studies in which the patients were neither female nor diagnosed 
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with Rett Syndrome.  Table 1 includes the demographics of the included studies.  Results were 
reported based on p-values, clinically importance (CI), relative risk reduction (RRR), absolute 
risk reduction (ARR), relative benefit increase (RBI), absolute benefit increase (ABI), and 
numbers needed to treat (NNT).  
Outcomes Measured 
The outcomes measured had to be POEMS, such as the positive effects of L-carnitine on 
physical well-being, motor skills, sleep efficiency, physical activity, and cardiac 
dysautonomia.
1,2,3
   To help measure these outcomes several tools were used.  The Rett 
Syndrome: Symptom Severity Index (RT:SSI), Patient Well-Being Index, and SF-36 Health 
Survey were used to measure the physical well being of participants.  The hand apraxia scale and 
RS Motor Behavioral Assessment were used to measure motor skills.  A 7 day-night sleep diary 
was kept to measure sleep efficiency.  TriTrac-R3D ergometers were used to measure physical 
activity and cardiac dysautonomia was measured using an electrocardiogram.  These tools were 
used by parents/caregivers to assess the outcomes of the trials.  To compare treatment score 
differences the Wilcoxon matched-pair, signed-rank test was used.
1,2,3 
Table 1. Demographics of Included Studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion Criteria Exclusion 
Criteria 
W/D Interventions 
Ellaway, 
1999 
Randomized, 
placebo-
controlled, 
double-blind 
crossover 
trial 
 
39 4-35 
yo 
Females 
diagnosed with 
Rett Syndrome  
None 4 Phase 1- Group 1 
received L-
carnitine and 
Group 2 received 
placebo both for 
an 8 week period 
followed by an 8 
week wash-out 
period.  Phase 2- 
Group 1 receive 
placebo and 
Group 2 received 
L-carnitine for an 
Mason, L-carnitine & Rett Syndrome      4 
 
8 week period.  
Ellaway, 
2001 
Cohort 21 7-41 
yo 
Females 
diagnosed with 
Rett Syndrome 
None 0 Subjects assessed 
before treatment 
and after a 6 
month treatment 
of L-carnitine 
with the Rett 
Syndrome 
Guideri, 
2005 
Randomized 
Control Trial 
22 2-21 
yo 
Females with Rett 
Syndrome whose 
diagnosis was 
confirmed by 2 
child 
neuropsychiatrists 
None 0 All participants 
initially treated 
with 
carbamazepine.  
Participants 
divided into 2 
groups: one 
group received 
Acetyl-L-
carnitine 
treatment for 6 
months and the 
other group was 
the control group.  
 
Results 
Two randomized controlled trials and one cohort trial are presented in this review, 
analyzed with intention to treat and with study participants being clinically diagnosed with Rett 
Syndrome.  Patients were seen in an outpatient setting in all trials and all participants were 
clinically diagnosed with Rett Syndrome.    
In the first Ellaway study, participants received 100 mg/kg/day of L-carnitine three times 
a day and in the follow-up study the same dosage was given twice a day.
1,2
  In the Guideri study 
participants received 50 mg/kg day.
3
  A total of four participants in all studies experienced very 
loose bowel movements so their L-carnitine dosage was lowered to 75 mg/kg/day; however, 
constipation is often a problem with Rett Syndrome so patients benefited from the mild 
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laxative.
1,2
  Four other families reported a fishy body or urine odor coming from their 
daughters.
1,2
    
Thirty five female participants completed the initial Ellaway trial.  The patient’s ages 
ranged between 4 and 35 years, with a median of 9 years.  At the end of the trial, the mean total 
plasma carnitine level was 43μmol/L with a range of 17 to 61μmol/L (normal, 35-65μmol/L).  
The mean increase in total plasma carnitine was 23μmol/L with a range of -5 to 68μmol/L.  The 
mean free plasma carnitine level was 36μmol/L with a range of 15-54μmol/L (normal, 30-
60μmol/L) and the mean increase in free plasma carnitine was 18μmol/L with a range of -4 to 
54μmol/L.  In all but three subjects the total and free plasma carnitine increased between pre- 
and post-treatment.  The outcome of the treatment was measured using the Wilcoxon matched-
pair, signed-rank tests.  The p-values for the Parent/Caregiver assessment as well as a medical 
follow-up are given in Table 2.
1
  
Table 2. Wilcoxon Matched-Pair, Signed-Rank Test Results  
 P Value of 
Parents/Caregivers 
P Value of Medical 
follow-up 
Rett Syndrome Motor Behavior 
Assessment  
  
Behavioral/social 0.091 0.006 
Orofacial/respiratory 0.087 0.018 
Motor assessment/physical signs 0.537 0.284 
Hand Apraxia Scale 0.228 0.058 
Patient Well-Being Index 0.015 0.000 
The change in status reported by parents and/or caregivers and at medical follow-up after 
completion of L-carnitine therapy compared to placebo can be seen in Table 3.  In the 
parent/caregiver completed questionnaires the only significant improvement seen was in the 
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subjects’ well-being when treated with L-carnitine relative to their status on the placebo.  At 
medical follow-up, more subjects improved than worsened in the behavioral/social subscale of 
the Rett Syndrome Motor Behavioral questionnaire. Using the Well-Being Index and Hand 
Apraxia scale significantly more children improved than worsened or stayed the same on L-
carnitine relative to the placebo.
1
   
Table 3. Change in Status After Completion of L-carnitine Therapy Compared to Status on 
Placebo 
 Improved Same Worse 
 Number Percent 
(95%CI) 
Number Percent 
(95% CI) 
Number  Percent 
(95% CI) 
Parent /Caregiver       
Rett Syndrome Motor 
Behavioral Assessment 
      
Behavioral/social 11 35.5  15 48.4 5 16.1 
Orofacial/respiratory 8 25.8 15 48.4 8 25.8 
Motor 
assessment/physical signs 
8 25.8 17 54.8 6 19.4 
Hand Apraxia Scale 6 19.4 15 48.4 10 32.3 
Patient Well-Being Index 17 54.8 9 29.0 5 16.1 
Medical follow-up       
Rett Syndrome Motor 
Behavioral Assessment 
      
Behavioral/social 19 54.3 12 34.3 4 11.4 
Orofacial/respiratory 15 42.9 13 37.1 7 20.0 
Motor 
assessment/physical signs 
19 54.3 8 22.9 8 22.9 
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Hand Apraxia Scale 28 80.0 1 2.9 6 17.1 
Patient Well-Being Index 25 71.4 8 22.9 2 5.7 
Treatment effects included relative benefit increase (RBI), absolute benefit increase 
(ABI), and numbers need to treat (NNT), whose calculation can be seen in Table 4. The RBI was 
found to be 1.86% and the ABI was 0.26%.  The NNT was found to be 4.
1
   
Table 4. Treatment effects of randomized, placebo-controlled, double-blind crossover trial 
CER EER RBI ABI NNT 
0.14% 0.4% 0.4%- 0.14% 
      0.14%     =  
1.86% 
0.4% -  0.14%= 0.26% 1/ 0.2%= 3.85= 4 
 
Twenty-one female participants completed the follow-up Ellaway study, with an 
additional 62 participants in a control group.  The participants ranged in age from 7 to 41 years, 
with a mean age of 14.4 years.  The mean total plasma carnitine concentration at the 
commencement of the trials was 35.2μmol/L, with a range of 16.0-54.0μmol/L.  At baseline, ten 
subjects had low total plasma carnitine.  In all cases the total carnitine concentrations increased 
between pre- and post treatment with L-carnitine.  Table 5 shows the results of paired t-tests and 
Wilcoxon matched-pair, signed-ranks tests for the RS:SSI, hand apraxia scale and sleep diary 
data.  Significant improvement in scores for the RS cases (P<0.05) was seen for sleep efficiency, 
sleep latency, and the proportion of total sleep that occurred during the day.  Significant 
improvement was seen in communication skills, energy level, teeth grinding, and expressive 
speech for RS cases based on the RS:SSI (P<0.05).  The SF-36 Health Survey and Hand Apraxia 
Scale for the cases or controls showed no significant changes.
2
   
Table 5.  Paired t-test and Wilcoxon matched-pair, signed-rank test results for outcome 
measures for cases and controls.   
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Outcome Measures RS cases RS cases: low plasma 
carnitine 
RS controls 
RS:SSI (N) 21 10 62 
Communication Skills 0.004 0.971 0.726 
Energy Level 0.001 0.689 0.500 
Teeth Grinding 0.002 0.419 0.565 
Expressive Speech  0.011 0.302 0.347 
Hand Apraxia Scale (N) 21 10 62 
 0.782 0.111 0.644 
Sleep Diary Data (N) 21 10 60 
Total sleep time 0.641 0.754 0.673 
Sleep latency 0.026 0.602 0.054 
Sleep efficiency 0.005 0.082 0.220 
SF-36 Health Survey (N) 18 10 62 
Physical functioning 0.269 0.659 0.060 
 
Ten females participated in the Guideri trial, along with 12 control patients.  The 
participants ranged in age from 2-21 years.  Heart rate variability (HRV), corrected QT interval 
(QTc), and QTc dispersion (QTcD) were measured by means of a t-test.  Three main spectral 
components were identified: very low-frequency (VLF) <0.04 Hz, low-frequency (LF) between 
0.04-0.15 Hz, and high-frequency component (HF) between 0.15-0.4 Hz.  Table 6 demonstrates 
the results of the trial group compared to the control group.  No significant differences between 
the trial and control groups existed at basal condition.  After 6-18 months, the control group had 
a significant reduction in total power spectrum of HRV (p=0.04) and the LF spectral variable 
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(p=0.05), but a significantly increased QTcD (p=0.01).  In the treatment group, there was a 
significant increase in total power, VLF, and LF spectral variables but no significant reduction in 
QTcD occurred.
3
   
Table 6. Comparison of spectral variables and QTc interval in control group and trial 
group at basal evaluation and after 6-18 months.    
 R-R 
interval 
Total 
Power 
(msec
2
) 
VLF 
(msec
2
) 
LF 
(msec
2
) 
HF 
(msec
2
) 
LF:HF QTc (sec) QTcD 
(sec) 
Control 
Group 
(n=12) 
p=0.06 p=0.04 p =0.6 p 
=0.05 
p =0.3 p=0.5 p =0.9 p=0.01 
Basal 
Evaluatio
n 
602 ± 
121 
1197± 
483 
332±47 470± 
236 
171±11
9 
4±2.6 0.429± 
0.02 
0.03± 
0.01 
After 6-18 
mo. 
584±78 830± 
343 
373± 
223 
286± 
195 
129± 
105 
5± 5 0.430 ± 
0.02 
0.05 ± 
0.02 
Trial 
Group 
p =0.6 p =0.01 p =0.01 p 
=0.009 
p =0.1 p=0.8 p =0.6 p =0.64 
Basal 
Evaluatio
n 
583±61  1004± 
430 
369± 
235 
369± 
181 
191± 
116 
2.3± 
1.2 
0.43± 0.04 0.039± 
0.01 
After 6-18 
mo. 
616± 61 3094± 
2108 
1003± 
697 
963± 
564 
796± 
1042 
2.2± 
1.8 
0.425± 
0.03 
0.036± 
0.01 
Treatment effects included the relative risk reduction (RRR), absolute risk reduction 
(ARR), and NNT, whose calculation can be seen in Table 7. The RRR was found to be -0.18% 
and the ARR was -0.1%.  The NNT was found to be -10.
3
   
Table 7. Treatment effects of randomized controlled trial 
CER EER RRR ARR NNT 
0.55% 0.45% 0.45% -0.55% 
       0.55%     = -
0.18% 
0.45%-0.55%= - 0.1% 1/-0.1%=  -10 
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Discussion  
The randomized controlled trials and cohort trial demonstrate that L-carnitine can be used 
to improve the quality of life in Rett Syndrome patients by improving symptoms and reducing 
the risk of sudden cardiac death.   
In the initial Ellaway study, there was improvement in the patient’s well-being according 
to parental and/or caregiver assessment but no other improvements were statistically significant.
1
  
The medical follow-up for this study showed significant improvement in the behavior/social and 
the orofacial/respiratory subscale of the Motor Behavioral Assessment and Hand Apraxia scale. 
Based on qualitative symptomatic data, 70% of parents reported subtle but important 
improvements in the quality of life of the subjects while on the L-carnitine phase of the trial.  
These improvements included improved eye contact and concentration span, lack of daytime 
somnolence, improved vocalization, increased mobility, and the perception that the girls were 
much happier.  Limitations of this study included subjective assessment tools which were 
insensitive to minor improvements in patients and potential unblinding of parents/caregivers and 
investigators due to the change in bowel habits of the subjects..
1
   
In the follow-up Ellaway study, Rett Syndrome patients treated with L-carnitine showed 
significant improvement over the 6 month period in sleep efficiency, sleep latency, proportion of 
total sleep that occurred during the day, energy level, communication skills, expressive language 
and teeth grinding.
2
  In this follow-up study established tools and the RS:SSI were used as 
objective outcome measures to assess the effects of L-carnitine on participants.  The RS:SSI is a 
more reliable and valid assessment tool when compared to those used to assess outcomes in the 
initial study.
2
  One limitation of the study was that the individual improvements of the girls could 
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have had significant impact on the patients as well as their families, thus affecting the subjective 
outcomes.   
The Guideri trial showed that L-carnitine had many effects on ECG parameters.  There 
was a significant increase in HRV total power and a slight reduction in sympathetic over-activity 
(expressed by LF:HF ratio) which can correlate with a reduction of the risk of cardiac 
arrhythmias is females with Rett Syndrome.
3
  A small sample size was studied for this trial 
which limits the overall validity of the study.   
L-carnitine is currently sold as a nutritional supplement and is used primarily for heart-
related conditions, such as angina.
3
 It has also been shown to have the potential to prevent 
myocardial sympathetic nervous dysfunction in diabetic patients.
3 
Conclusion 
 Based on the three trials, L-carnitine does improve the quality of life in patients with Rett 
Syndrome.  Since there were no baseline criteria for the severity of Rett Syndrome in 
participants, the effects of the L-carnitine were varied.  Further studies need to be investigated in 
which L-carnitine is used for longer than a 6-month period in order to observe any long term 
effects of the medication and a baseline severity of Rett Syndrome needs to be established for 
participants.  Also, researchers need to investigate a way to minimize subjective data in order to 
have the data be more statistically significant.  Mortality rates and/or annual hospital visits 
should be included in future studies of the effect of L-carnitine on cardiac dysautonomia in order 
to demonstrate the effect of treatment on patient outcomes. 
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